zamtocabtagene autoleucel (mb-cart2019.1): a novel car-t approach in r/r b-nhl
Published 3 years ago • 166 plays • Length 3:36Download video MP4
Download video MP3
Similar videos
-
1:33
zamtocabtagene autoleucel for the treatment of patients with r/r dlbcl
-
0:57
zamtocabtagene autoleucel: mechanism of production & potential implications for access
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t
-
1:06
how will novel agents & car-t cells affect the future treatment landscape in b-all?
-
2:13
interim analysis of phase ii study of zamto-cel in r/r dlbcl
-
0:32
state-of-the-art car-t therapy for b-all
-
2:06
odronextamab in car-t relapsed diffuse large b-cell lymphoma
-
1:34
advances and unmet needs in second-line treatment of dlbcl
-
![[dentium] ct viewer_bright 3d viewer manual_cross](https://i.ytimg.com/vi/SGeD_bPR64g/mqdefault.jpg)
9:33
[dentium] ct viewer_bright 3d viewer manual_cross
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
6:45
amir bluetooth fm transmitter
-
1:06
epcore nhl-1: two and a half year follow-up of epcoritamab in dlbcl
-
2:49
cd19 car-t therapy drives the expansion of clonal hematopoiesis and associated cytopenias in lbcl
-
1:04
horizon scan of novel and upcoming aml therapies
-
2:05
the cost-effectiveness of car t-cell therapy
-
1:33
real-world multicenter study of caplacizumab in patients with acquired ttp
-
1:03
insights into the cartitude-6 trial: rationale and design
-
1:41
the challenges with implementing car-t into the aml treatment landscape
-
3:38
finding the expansion balance: car t-cell response markers identified from the trial of jcar017
-
4:55
ebmt 2020: cellular therapy day
-
1:08
an insight into the mutational landscape and unique features of cmml